|
|
|
Xtalks, Online
2024-10-29
In the rapidly evolving field of drug discovery, artificial intelligence (AI) and machine learning (ML) have become well-known multipliers in accelerating research and enhancing the development of therapeutic compounds.
This talk will explore Revvity Signals’ strategic journey and share details of existing AI/ML integrations into current Revvity Signals’ software solutions. The team will also discuss the future picture and direction of travel for AI/ML and their software solutions. The speakers will share their future direction and pipeline and explore how these solutions will continue to empower scientists to drive significant breakthroughs in drug discovery.
They will share their insights into the opportunities afforded by AI/ML. Specifically, they will provide examples of how these tools are currently assisting researchers in their daily work in two ways: 1) to help scientists document or efficiently use the software and 2) to help scientists accelerate their science.
They will also discuss about augmented intelligence, where AI and ML tools complement and enhance human expertise rather than replace it. The goal of augmented intelligence is to create solutions that support decision-making processes and accelerate routine tasks, allowing researchers to dedicate more time to higher-level analysis and creative problem-solving.
Register for this webinar today to discover how cutting-edge AI and ML technologies are being leveraged for drug discovery and development.
Keywords: Drug Development, Drug Discovery, CRO, Drug Manufacturing, Medicinal Chemistry, AI, Analytical Chemistry, Data Science, Small Molecule Drug Discovery, Basic Research
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
Invited Speakers:
|
|
Zev Wisotsky, Director of Drug Discovery Informatics, Revvity Signals David Gosalvez, PhD, Executive Director, Strategy & Informatics Portfolio, Revvity Signals
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-29
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|